Table 1.

Baseline characteristics of advanced NSCLC PDL1 TPS ≥50% patients by pembrolizumab treatment schedule.

Entire Cohort (n = 718)	Q3W n = 677	Q6W n = 41	p-Value
Age at diagnosis (median) years	70	70	0.957
Sex			0.072
Female	372 (55%)	15 (37%)
Male	305 (45%)	26 (63%)
Smoking status			0.274
Never	43 (6%)	1 (2%)
Former	492 (73%)	29 (71%)
Current	124 (18%)	8 (20%)
Unknown	18 (3%)	3 (7%)
Smoking (median) years			0.596
ECOG PS			0.037
0–1	399 (59%)	23 (56%)
≥2	260 (38%)	14 (34%)
Unknown	18 (3%)	4 (10%)
Histology			0.608
Squamous	138 (20%)	7 (17%)
Non-squamous	539 (80%)	34 (83%)